Patrick McEnany - Catalyst Pharmaceuticals Co-Founder, Chairman, CEO and Pres

CPRX Stock  USD 22.89  1.23  5.68%   

Chairman

Mr. Patrick James McEnany is the Chairman of the Board, President, Chief Executive Officer of Catalyst Pharmaceutical Partners, Inc. Mr. McEnany is a cofounder of our company and currently serves as our Chairman, President and Chief Executive Officer since 2006.
Age 77
Tenure 19 years
Address 355 Alhambra Circle, Coral Gables, FL, United States, 33134
Phone305 420 3200
Webhttps://www.catalystpharma.com
McEnany was our CEO and a director since our formation in January 2002. He became Chairman and President in March 2006. From 1999 to 2002, Mr. McEnany was a consultant to the pharmaceutical industry. From 1991 to 1997, Mr. McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr. McEnany served as president of the whollyowned Royce Laboratories subsidiary and vice president of corporate development for Watson Pharmaceuticals, Inc. From 1993 to 1997, he also served as vice chairman and a director of the National Association of Pharmaceutical Manufacturers. He currently serves on the board of directors of the Jackson Health Foundation and the Humane Society of Greater Miami, and over the last 30 years has served as a director for numerous public companies. The Board believes the characteristics that qualify Mr

Patrick McEnany Latest Insider Activity

Tracking and analyzing the buying and selling activities of Patrick McEnany against Catalyst Pharmaceuticals stock is an integral part of due diligence when investing in Catalyst Pharmaceuticals. Patrick McEnany insider activity provides valuable insight into whether Catalyst Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Catalyst Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalyst Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Catalyst Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.1846 % which means that it generated a profit of $0.1846 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2938 %, meaning that it created $0.2938 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.25 in 2025. Return On Capital Employed is likely to rise to 0.28 in 2025. At this time, Catalyst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 654.8 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.
Catalyst Pharmaceuticals currently holds 2.79 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Catalyst Pharmaceuticals has a current ratio of 10.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Catalyst Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 7 records

CHAIRMAN Age

Richard MDX4 Pharmaceuticals
63
Douglas TrecoInozyme Pharma
67
Yves SabbaghInozyme Pharma
N/A
Herriot MDAxsome Therapeutics
57
John CPAHepion Pharmaceuticals
77
Stelios PapadopoulosExelixis
77
Herve HoppenotIncyte
65
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. Catalyst Pharmaceuticals (CPRX) is traded on NASDAQ Exchange in USA. It is located in 355 Alhambra Circle, Coral Gables, FL, United States, 33134 and employs 14 people. Catalyst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Catalyst Pharmaceuticals Leadership Team

Elected by the shareholders, the Catalyst Pharmaceuticals' board of directors comprises two types of representatives: Catalyst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalyst. The board's role is to monitor Catalyst Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catalyst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalyst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Philip Schwartz, Co Sec
CMA CPA, VP, Officer
Pete Sr, Vice Sales
Richard MBA, CEO President
Mary Coleman, VP Relations
Stanley MD, Senior Discovery
Philip Esq, Corporate Secretary
Gary MD, Chief Officer
Jeffrey Carmen, Executive Officer
Michael CPA, Executive CFO
Preethi Sundaram, Chief Officer
Patrick McEnany, Co-Founder, Chairman, CEO and Pres
Steven Miller, COO and Chief Scientific Officer
Brian JD, Chief Officer

Catalyst Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalyst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.